Biomarkers in major depressive disorder: The role of mass spectrometry

Advances in Experimental Medicine and Biology

Volumn 806, Issue , 2014, Pages 545-560

  Woods, Alisa G ^a,b   Iosifescu, Dan V ^c   Darie, Costel C ^a  

^a CLARKSON UNIVERSITY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL NAV1.7; VENLAFAXINE;

ARTICLE; BLOOD COMPONENT; CEREBROSPINAL FLUID ANALYSIS; DISEASE MODEL; DRUG CHOICE; DRUG EFFECT; HUMAN; MAJOR DEPRESSION; MASS SPECTROMETRY; MEDICAL RESEARCH; METABOLOMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEOMICS; URINALYSIS; WESTERN BLOTTING; ANIMAL; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84907424520     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-06068-2_27     Document Type: Article

References (107)

1. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21:169-184
2. To SE, Zepf RA, Woods AG (2005) The symptoms, neurobiology, and current pharmacological treatment of depression. J Neurosci Nurs 37:102-107
3. APA (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Arlington, VA
4. Woods AG (2004) Understanding depression and diabetes. Diabetes Self Manag 21:6, 8, 11-12
5. Strine TW, Mokdad AH, Balluz LS, Gonzalez O, Crider R, Berry JT et al (2008) Depression and anxiety in the United States: findings from the 2006 Behavioral Risk Factor Surveillance System. Psychiatr Serv 59:1383-1390
6. Niranjan A, Corujo A, Ziegelstein RC, Nwulia E (2012) Depression and heart disease in US adults. Gen Hosp Psychiatry 34:254-261
7. Mathew CS, Dominic M, Isaac R, Jacob JJ (2012) Prevalence of depression in consecutive patients with type 2 diabetes mellitus of 5-year duration and its impact on glycemic control. Indian J Endocrinol Metab 16:764-768
8. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627
9. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105
10. Chapman D, Perry G, Strine T (2005) The vital link between chronic disease and depressive disorders. Prev Chronic Dis 2:A14
11. Shim RS, Baltrus P, Ye J, Rust G (2011) Prevalence, treatment, and control of depressive symptoms in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2005-2008. J Am Board Fam Med 24:33-38
12. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D (2003) Cost of lost productive work time among US workers with depression. JAMA 289:3135-3144
13. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC (2005) Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:629-640
14. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905-1917
15. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M et al (2006) Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 67:185-195
16. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D et al (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243-1252
17. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME et al (2006) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242
18. Woods AG (2008) Give a man a fish. Essential fatty acids in health and disease. Diabetes Self Manag 25:8, 11-12, 14
19. Roth R (2012) Lisdexamfetamine dimesylate augmentation for executive dysfunction in adults with fully or partially remitted major depressive disorder. In: The 165th annual meeting of the American Psychiatric Association, Philadelphia, PA
20. Piet J, Hougaard E (2011) The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev 31:1032-1040
21. Pehrson AL, Sanchez C (2013) Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 19(2):121-133
22. Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CM, Perez AM et al (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134-1142
23. Mantione E, Micheloni S, Alcaino C, New K, Mazzaferro S, Bermudez I (2012) Allosteric modulators of alpha4beta2 nicotinic acetylcholine receptors: a new direction for antidepressant drug discovery. Future Med Chem 4:2217-2230
24. Keefe R (2012) Lisdexamfetamine dimesylate in the treatment of cognitive dysfunction in patients with partially or fully remitted major depressive disorder. In: 165th annual meeting of the American Psychiatric Association, Philadelphia, PA
25. Celada P, Bortolozzi A, Artigas F (2013) Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27:703-716
26. Martins-De-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T et al (2010) Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry 11:719-728
27. Pallis AG, Fennell DA, Szutowicz E, Leighl NB, Greillier L, Dziadziuszko R (2011) Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer 105:1-8
28. Phillips KA, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ et al (2009) Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 115:5166-5174
29. Ross JS (2011) Biomarker-based selection of therapy for colorectal cancer. Biomark Med 5:319-332
30. Lakhan SE, Vieira K, Hamlat E (2010) Biomarkers in psychiatry: drawbacks and potential for misuse. Int Arch Med 3:1
31. Singh I, Rose N (2009) Biomarkers in psychiatry. Nature 460:202-207
32. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J et al (2012) Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 16:1184-1195
33. Cook IA, Hunter AM, Gilmer WS, Iosifescu DV, Zisook S, Burgoyne KS et al (2013) Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identifi - cation of treatment effectiveness in major depression (BRITE-MD) trial. J Clin Psychiatry 74:51-56
34. Greenblatt JM, Sussman C, Jameson M, Yuan L, Hoffman DA, Iosifescu DV (2011) Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders. Neuropsychiatr Dis Treat 7:529-541
35. Iosifescu DV (2011) Electroencephalography-derived biomarkers of antidepressant response. Harv Rev Psychiatry 19:144-154
36. Hoogenboom WS, Perlis RH, Smoller JW, Zeng-Treitler Q, Gainer VS, Murphy SN et al (2014) Limbic system white matter microstructure and long-term treatment outcome in major depressive disorder: a diffusion tensor imaging study using legacy data. World J Biol Psychiatry 15:122-134
37. Blood AJ, Iosifescu DV, Makris N, Perlis RH, Kennedy DN, Dougherty DD et al (2010) Microstructural abnormalities in subcortical reward circuitry of subjects with major depressive disorder. PLoS One 5:e13945
38. Barnett JH, Smoller JW (2009) The genetics of bipolar disorder. Neuroscience 164: 331-343
39. Kvajo M, McKellar H, Gogos JA (2010) Molecules, signaling, and schizophrenia. Curr Top Behav Neurosci 4:629-656
40. Poelmans G, Pauls DL, Buitelaar JK, Franke B (2011) Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry 168:365-377
41. Weber H, Kittel-Schneider S, Gessner A, Domschke K, Neuner M, Jacob CP et al (2011) Cross-disorder analysis of bipolar risk genes: further evidence of DGKH as a risk gene for bipolar disorder, but also unipolar depression and adult ADHD. Neuropsychopharmacology 36:2076-2085
42. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE (2010) Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 167:509-527
43. Kolassa IT, Kolassa S, Ertl V, Papassotiropoulos A, De Quervain DJ (2010) The risk of posttraumatic stress disorder after trauma depends on traumatic load and the catechol-omethyltransferase Val(158)Met polymorphism. Biol Psychiatry 67:304-308
44. Lahey BB, Rathouz PJ, Lee SS, Chronis-Tuscano A, Pelham WE, Waldman ID et al (2011) Interactions between early parenting and a polymorphism of the child's dopamine transporter gene in predicting future child conduct disorder symptoms. J Abnorm Psychol 120:33-45
45. Roy A, Sarchiopone M, Carli V (2009) Gene-environment interaction and suicidal behavior. J Psychiatr Pract 15:282-288
46. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM et al (2013) A mega-analysis of genomewide association studies for major depressive disorder. Mol Psychiatry 18:497-511
47. Anderson L, Seilhamer J (1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18:533-537
48. Junaid MA, Pullarkat RK (2001) Proteomic approach for the elucidation of biological defects in autism. J Autism Dev Disord 31:557-560
49. Ngounou Wetie AG, Sokolowska I, Wormwood K, Michel TM, Thome J, Darie CC et al (2013) Mass spectrometry for the detection of potential psychiatric biomarkers. J Mol Psychiatry 1:8
50. Woods AG, Ngounou Wetie AG, Sokolowska I, Russell S, Ryan JP, Michel TM et al (2013) Mass spectrometry as a tool for studying autism spectrum disorder. J Mol Psychiatry 1:6
51. Darie C (2013) Investigation of protein-protein interactions by blue native-PAGE & mass spectrometry. Mod Chem Appl 1:e111
52. Darie CC, Biniossek ML, Gawinowicz MA, Milgrom Y, Thumfart JO, Jovine L et al (2005) Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg. J Biol Chem 280:37585-37598
53. Darie CC, Biniossek ML, Jovine L, Litscher ES, Wassarman PM (2004) Structural characterization of fish egg vitelline envelope proteins by mass spectrometry. Biochemistry 43:7459-7478
54. Darie CC, Biniossek ML, Winter V, Mutschler B, Haehnel W (2005) Isolation and structural characterization of the Ndh complex from mesophyll and bundle sheath chloroplasts of Zea mays. FEBS J 272:2705-2716
55. Darie CC, Deinhardt K, Zhang G, Cardasis HS, Chao MV, Neubert TA (2011) Identifying transient protein-protein interactions in EphB2 signaling by blue native PAGE and mass spectrometry. Proteomics 11:4514-4528
56. Darie CC, Janssen WG, Litscher ES, Wassarman PM (2008) Purified trout egg vitelline envelope proteins VEbeta and VEgamma polymerize into homomeric fibrils from dimers in vitro. Biochim Biophys Acta 1784:385-392
57. Darie CC, Litscher ES, Wassarman PM (2008) Structure, processing, and polymerization of rainbow trout egg vitelline envelope proteins. Nato Scie Peace Secu 23-36
58. Darie CC, Shetty V, Spellman DS, Zhang GJ, Xu CF, Cardasis HL et al (2008) Blue native page and mass spectrometry analysis of ephrin stimulation-dependent protein-protein interactions in Ng108-Ephb2 cells. Nato Scie Peace Secu 3-22
59. Ngounou Wetie AG, Sokolowska I, Woods AG, Darie CC (2013) Identification of posttranslational modifications by mass spectrometry. Aust J Chem 66:734-748
60. Ngounou Wetie AG, Sokolowska I, Woods AG, Roy U, Deinhardt K, Darie CC (2014) Protein-protein interactions: switch from classical methods to proteomics and bioinformaticsbased approaches. Cell Mol Life Sci 71:205-228
61. Ngounou Wetie AG, Sokolowska I, Woods AG, Roy U, Loo JA, Darie CC (2013) Investigation of stable and transient protein-protein interactions: past, present, and future. Proteomics 13:538-557
62. Ngounou Wetie AG, Sokolowska I, Woods AG, Wormwood KL, Dao S, Patel S et al (2013) Automated mass spectrometry-based functional assay for the routine analysis of the secretome. J Lab Autom 18:19-29
63. Sokolowska I, Dorobantu C, Woods AG, Macovei A, Branza-Nichita N, Darie CC (2012) Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells. Proteome Sci 10:47
64. Sokolowska I, Gawinowicz MA, Ngounou Wetie AG, Darie CC (2012) Disulfide proteomics for identification of extracellular or secreted proteins. Electrophoresis 33:2527-2536
65. Sokolowska I, Ngounou Wetie AG, Roy U, Woods AG, Darie CC (1834) Mass spectrometry investigation of glycosylation on the NXS/T sites in recombinant glycoproteins. Biochim Biophys Acta 2013:1474-1483
66. Sokolowska I, Ngounou Wetie AG, Woods AG, Darie CC (2012) Automatic determination of disulfide bridges in proteins. J Lab Autom 17:408-416
67. Sokolowska I, Ngounou Wetie AG, Woods AG, Darie CC (2013) Applications of mass spectrometry in proteomics. Aust J Chem 66:721-733
68. Sokolowska I, Ngounou Wetie AG, Wormwood K, Michel TM, Thome J, Darie CC et al (2013) The potential of biomarkers in psychiatry: focus on proteomics. J Neural Transm. [Epub ahead of print]
69. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells. J Biol Chem 287:1719-1733
70. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2013) Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R). Cell Mol Life Sci 70:2835-2848
71. Sokolowska I, Woods AG, Wagner J, Dorler J, Wormwood K, Thome J et al (2011) Mass spectrometry for proteomics-based investigation of oxidative stress and heat shock proteins. In: Andreescu S, Hepel M (eds) Oxidative stress: diagnostics, prevention, and therapy. American Chemical Society, Washington, DC
72. Woods AG, Sokolowska I, Deinhardt K, Sandu C, Darie CC (2013) Identification of tumor differentiation factor (TDF) in select CNS neurons. Brain Struct Funct. [Epub ahead of print]
73. Woods AG, Sokolowska I, Yakubu R, Butkiewicz M, LaFleur M, Talbot C et al (2011) Blue native page and mass spectrometry as an approach for the investigation of stable and transient protein-protein interactions. In: Andreescu S, Hepel M (eds) Oxidative stress: diagnostics, prevention, and therapy. American Chemical Society, Washington, DC
74. Roy U, Sokolowska I, Woods AG, Darie CC (2012) Structural investigation of tumor differentiation factor. Biotechnol Appl Biochem 59:445-450
75. Taurines R, Dudley E, Grassl J, Warnke A, Gerlach M, Coogan AN et al (2011) Proteomic research in psychiatry. J Psychopharmacol 25:151-196
76. Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A et al (2014) Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatmentresistant depression. Int J Neuropsychopharmacol 17(2):331-336
77. Kazuno AA, Ohtawa K, Otsuki K, Usui M, Sugawara H, Okazaki Y et al (2013) Proteomic analysis of lymphoblastoid cells derived from monozygotic twins discordant for bipolar disorder: a preliminary study. PLoS One 8:e53855
78. Woods AG, Poulsen FR, Gall CM (1999) Dexamethasone selectively suppresses microglial trophic responses to hippocampal deafferentation. Neuroscience 91:1277-1289
79. Woods AG, Guthrie KM, Kurlawalla MA, Gall CM (1998) Deafferentation-induced increases in hippocampal insulin-like growth factor-1 messenger RNA expression are severely attenuated in middle aged and aged rats. Neuroscience 83:663-668
80. Schneider B, Prvulovic D (2013) Novel biomarkers in major depression. Curr Opin Psychiatry 26:47-53
81. Yoshida T, Ishikawa M, Niitsu T, Nakazato M, Watanabe H, Shiraishi T et al (2012) Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One 7:e42676
82. Kotan Z, Sarandol E, Kirhan E, Ozkaya G, Kirli S (2012) Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther Adv Psychopharmacol 2:65-74
83. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J et al (2011) Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16:1088-1095
84. Huang TL, Lee CT, Liu YL (2008) Serum brain-derived neurotrophic factor levels in patients with major depression: effects of antidepressants. J Psychiatr Res 42:521-525
85. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM (2002) Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res 109:143-148
86. Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N et al (2013) Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry 73:1213-1221
87. Harmer CJ, Cowen PJ (2013) 'It's the way that you look at it'-a cognitive neuropsychological account of SSRI action in depression. Philos Trans R Soc Lond B Biol Sci 368:20120407
88. Mu J, Xie P, Yang ZS, Yang DL, Lv FJ, Luo TY et al (2007) Neurogenesis and major depression: implications from proteomic analyses of hippocampal proteins in a rat depression model. Neurosci Lett 416:252-256
89. Posener JA, Wang L, Price JL, Gado MH, Province MA, Miller MI et al (2003) Highdimensional mapping of the hippocampus in depression. Am J Psychiatry 160:83-89
90. Henningsen K, Palmfeldt J, Christiansen S, Baiges I, Bak S, Jensen ON et al (2012) Candidate hippocampal biomarkers of susceptibility and resilience to stress in a rat model of depression. Mol Cell Proteomics 11:M111.016428
91. Alawam K, Dudley E, Donev R, Thome J (2012) Protein and peptide profiling as a tool for biomarker discovery in depression. Electrophoresis 33:3830-3834
92. Kekesi KA, Juhasz G, Simor A, Gulyassy P, Szego EM, Hunyadi-Gulyas E et al (2012) Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide. PLoS One 7:e50532
93. Martins-de-Souza D, Guest PC, Harris LW, Vanattou-Saifoudine N, Webster MJ, Rahmoune H et al (2012) Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2:e87
94. Ditzen C, Tang N, Jastorff AM, Teplytska L, Yassouridis A, Maccarrone G et al (2012) Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 37:1013-1025
95. Xu HB, Zhang RF, Luo D, Zhou Y, Wang Y, Fang L et al (2012) Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int J Neuropsychopharmacol 15:1413-1425
96. Nichkova MI, Huisman H, Wynveen PM, Marc DT, Olson KL, Kellermann GH (2012) Evaluation of a novel ELISA for serotonin: urinary serotonin as a potential biomarker for depression. Anal Bioanal Chem 402:1593-1600
97. Hu S, Li Y, Wang J, Xie Y, Tjon K, Wolinsky L et al (2006) Human saliva proteome and transcriptome. J Dent Res 85:1129-1133
98. Shi M, Sui YT, Peskind ER, Li G, Hwang H, Devic I et al (2011) Salivary tau species are potential biomarkers of Alzheimer's disease. J Alzheimers Dis 27:299-305
99. Castagnola M, Messana I, Inzitari R, Fanali C, Cabras T, Morelli A et al (2008) Hypophosphorylation of salivary peptidome as a clue to the molecular pathogenesis of autism spectrum disorders. J Proteome Res 7:5327-5332
100. Grynderup MB, Kolstad HA, Mikkelsen S, Andersen JH, Bonde JP, Buttenschon HN et al (2013) A two-year follow-up study of salivary cortisol concentration and the risk of depression. Psychoneuroendocrinology 38:2042-2050
101. Xu HB, Fang L, Hu ZC, Chen YC, Chen JJ, Li FF et al (2012) Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res 200:1054-1057
102. Zheng P, Gao HC, Li Q, Shao WH, Zhang ML, Cheng K et al (2012) Plasma metabonomics as a novel diagnostic approach for major depressive disorder. J Proteome Res 11:1741-1748
103. Ellis MJ, Gillette M, Carr SA, Paulovich AG, Smith RD, Rodland KK et al (2013) Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov 3:1108-1112
104. Lo LH, Huang TL, Shiea J (2009) Acid hydrolysis followed by matrix-assisted laser desorption/ ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression. Rapid Commun Mass Spectrom 23:589-598
105. Huang TL, Cho YT, Su H, Shiea J (2013) Principle component analysis combined with matrix-assisted laser desorption ionization mass spectrometry for rapid diagnosing the sera of patients with major depression. Clin Chim Acta 424:175-181
106. Khawaja X, Xu J, Liang JJ, Barrett JE (2004) Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J Neurosci Res 75:451-460
107. Lim SW, Kim S, Carroll BJ, Kim DK (2013) T-lymphocyte CREB as a potential biomarker of response to antidepressant drugs. Int J Neuropsychopharmacol 16:967-974